Seelos Therapeutics Inc SEEL:NASDAQ

RT Quote | NASDAQ | USD
Last | 02/25/21 EST
3.05quote price arrow down-0.29 (-8.68%)
Volume
2,077,816
52 week range
0.42 - 4.44

...

Loading . . .

KEY STATS

  • Open3.39
  • Day High3.39
  • Day Low2.97
  • Prev Close3.05
  • 52 Week High4.44
  • 52 Week High Date02/16/21
  • 52 Week Low0.42
  • 52 Week Low Date04/02/20
  • Market Cap219.81M
  • Shares Out72.07M
  • 10 Day Average Volume3.90M
  • Dividend-
  • Dividend Yield-
  • Beta2.64
  • 1 Year % Change224.47

RATIOS/PROFITABILITY

  • EPS (TTM)-0.71
  • P/E (TTM)-4.31
  • Fwd P/E (NTM)-8.59
  • EBITDA (MRQ)-23.244M
  • ROE (MRQ)-273.59%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)79.21%
  • Net Margin (MRQ)-5,984.27%
  • Debt To Equity (MRQ)2.20%

EVENTS

  • Earnings Date03/16/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Seelos Therapeutics Inc News

There is no recent news for this security.

Latest SEEL News From Our Partners

QUOTE FINDER

Profile

MORE
Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic...
Raj Mehra
Chairman
Address
300 Park Avenue
New York, NY
10017
United States